Gilead Sciences (NASDAQ:GILD) Sees Positive Outlook from Morgan Stanley with a New Price Target
Summary
Morgan Stanley analyst Terence Flynn has set a $135 price target for Gilead Sciences (GILD), representing a potential 25% upside. This positive outlook is primarily driven by the recent FDA approval of Gilead's drug Yeztugo, which is expected to enhance the company's market position and financial performance. The stock is currently trading around $108, with active investor interest following the news.
Morgan Stanley Sets Bullish Price Target for Gilead Sciences (GILD) Following FDA Approval
FOSTER CITY, CA – Gilead Sciences (NASDAQ:GILD), a leading biopharmaceutical company specializing in treatments for HIV, liver diseases, and cancer, is receiving a positive outlook from Wall Street analysts. The company, a significant player in the pharmaceutical industry alongside competitors like Pfizer and Merck, is currently trading at approximately $108 per share.
On June 18, 2025, Morgan Stanley analyst Terence Flynn issued a new price target of $135 for Gilead Sciences. This target suggests a potential upside of approximately 25% from the stock's current trading level.
Key Drivers for the Positive Outlook
The optimistic stance from Morgan Stanley is significantly influenced by recent positive developments for Gilead, most notably the U.S. Food and Drug Administration (FDA) approval of Yeztugo. Morgan Stanley highlighted this approval as a crucial step forward for Gilead, expected to bolster its market position and contribute to future growth.
Impact of Yeztugo Approval
The FDA approval of Yeztugo is considered a major milestone for Gilead. This regulatory success aligns with investor expectations and is anticipated to positively impact the company's financial performance and market capitalization, which currently stands at approximately $134.3 billion.
Market Performance and Investor Activity
Gilead's stock has shown dynamic trading activity. Recent trading has seen the stock fluctuate between a low of $107.2 and a high of $111.78, indicating active investor interest in the company's prospects. Over the past year, the stock has experienced a wider range, trading between a high of $119.96 and a low of $64.86.
Despite these fluctuations, the company's established market position and the recent positive regulatory news provide a solid foundation for potential future appreciation. Today's trading volume of 11,816,865 shares further underscores active investor engagement and supports the positive sentiment surrounding Gilead's stock following the analyst's report and the FDA approval.
This analyst upgrade and the positive regulatory news are expected to contribute to continued investor focus on Gilead Sciences as it leverages its recent product approval for future growth.